Conventional therapies for metabolic disorders, such as lifestyle interventions, Glucagon-like peptide-1 (GLP-1) agonists, and sodium–glucose transport protein 2 (SGLT2) inhibitors, offer partial relief but are limited by side effects, high costs, and variable efficacy [6,7]. This evidence concerns the gene GCG and metabolic disease.